Ondine Biomedical Inc
LSE:OBI
Ondine Biomedical Inc
Research & Development
Ondine Biomedical Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Research & Development
-CA$9.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Research & Development
$14k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Research & Development
-$21m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-19%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Research & Development
-CA$2.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
MedMira Inc
XTSX:MIR
|
Research & Development
-CA$965.6k
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
3%
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Research & Development
-$15.3m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
6%
|
|
Ondine Biomedical Inc
Glance View
Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.
See Also
What is Ondine Biomedical Inc's Research & Development?
Research & Development
-9.2m
CAD
Based on the financial report for Dec 31, 2024, Ondine Biomedical Inc's Research & Development amounts to -9.2m CAD.
What is Ondine Biomedical Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-23%
Over the last year, the Research & Development growth was -79%. The average annual Research & Development growth rates for Ondine Biomedical Inc have been -23% over the past three years .
